Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
More News related to AGN
- Spectrum Pharma (SPPI) and Handok Pharma Announce Plans for Apaziquone Development in South Korea
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
More News related to AMGN
- Amgen Highlights Data to be Presented at ASH
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
- Amgen to Present at Lazard Capital Healthcare Conference
- Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
More News related to BIIB
- InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
- Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
- Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
More News related to Insiders' Blog
- Boenning & Scattergood Downgrades NutriSystem (NTRI) to Neutral
- Raymond James Upgrades Newpark Resources (NR) to Outperform
- Raymond James Upgrades Culp (CFI) to Strong Buy
- Satyam (SAY) Jumps 5% as JPMorgan Issues Intraday Upgrade
- Credit Suisse Upgrades MDC Holdings (MDC) to Neutral, $29 Target
According to reports the Wall Street Journal's Deal Journal, Sanofi-Aventis (NYSE: SNY) is on the prowl for a mega-deal in the U.S, citing reports in French business newspaper Les Echos.
Deal Journal said one obvious takeover target is Bristol-Myers Squibb (NYSE: BMY), since the two companies already have an existing partnership developing blood clot drug Plavix. Amgen (Nasdaq: AMGN) is seen as another possible takeover candidate.
European bankers said a deal to acquire Amgen could jeopardize Sanofi’s investment-grade credit rating.
Other more likely takeover targets include botox-maker Allergan (NYSE: AGN) or biotech company Biogen Idec (Nasdaq: BIIB), where activist investor Carl Icahn just won two board seats.
Link to WSJ Deal Journal Article
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Insiders' BlogRumors
Stocks Mentioned
-0.28
+0.42Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
